Fulton Bank N.A. Has $373,000 Stock Position in Avantor, Inc. (NYSE:AVTR)

Fulton Bank N.A. cut its holdings in Avantor, Inc. (NYSE:AVTR) by 10.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,579 shares of the company’s stock after selling 1,768 shares during the period. Fulton Bank N.A.’s holdings in Avantor were worth $373,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AVTR. Envestnet Portfolio Solutions Inc. bought a new position in shares of Avantor in the 3rd quarter valued at about $1,467,000. Envestnet Asset Management Inc. grew its stake in Avantor by 46.2% in the third quarter. Envestnet Asset Management Inc. now owns 932,213 shares of the company’s stock valued at $19,651,000 after purchasing an additional 294,739 shares in the last quarter. Invesco Ltd. increased its position in shares of Avantor by 56.5% during the 3rd quarter. Invesco Ltd. now owns 6,591,898 shares of the company’s stock worth $138,957,000 after purchasing an additional 2,381,154 shares during the last quarter. Mariner LLC raised its stake in shares of Avantor by 17.3% during the 3rd quarter. Mariner LLC now owns 42,025 shares of the company’s stock worth $886,000 after purchasing an additional 6,196 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Avantor by 9.0% in the 3rd quarter. Northern Trust Corp now owns 4,129,447 shares of the company’s stock valued at $87,049,000 after buying an additional 342,553 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Stock Performance

NYSE:AVTR opened at $22.12 on Friday. The stock has a 50 day simple moving average of $23.99 and a 200 day simple moving average of $23.76. The stock has a market cap of $15.03 billion, a P/E ratio of 56.72, a PEG ratio of 2.19 and a beta of 1.35. Avantor, Inc. has a 1-year low of $16.63 and a 1-year high of $26.16. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94.

Avantor (NYSE:AVTR) last posted its earnings results on Friday, April 26th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.68 billion. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The company’s revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.29 earnings per share. Research analysts anticipate that Avantor, Inc. will post 1.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Barclays boosted their target price on shares of Avantor from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Thursday, April 18th. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Finally, Evercore ISI lifted their price target on Avantor from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $26.71.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.